BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $195
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $187 to $195.
February 05, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on AbbVie and raises the price target from $187 to $195.
The upgrade in the price target by BMO Capital indicates a strong confidence in AbbVie's future performance. This is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100